{"protocolSection":{"identificationModule":{"nctId":"NCT04634669","orgStudyIdInfo":{"id":"AXS-05-TRD-202"},"organization":{"fullName":"Axsome Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)","officialTitle":"An Open-Label Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Treatment Resistant Depression"},"statusModule":{"statusVerifiedDate":"2026-01","overallStatus":"TERMINATED","whyStopped":"This study was terminated once overall program objectives were met.","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-09-23","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-02-18","type":"ACTUAL"},"completionDateStruct":{"date":"2022-03-04","type":"ACTUAL"},"studyFirstSubmitDate":"2020-11-12","studyFirstSubmitQcDate":"2020-11-12","studyFirstPostDateStruct":{"date":"2020-11-18","type":"ACTUAL"},"resultsFirstSubmitDate":"2025-03-03","resultsFirstSubmitQcDate":"2026-01-12","resultsFirstPostDateStruct":{"date":"2026-01-28","type":"ACTUAL"},"dispFirstSubmitDate":"2023-03-03","dispFirstPostDateStruct":{"date":"2026-01-28","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-01-12","lastUpdatePostDateStruct":{"date":"2026-01-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Axsome Therapeutics, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This study is a multi-center, open-label trial to evaluate the long-term safety and efficacy of AXS-05 in subjects with major depressive disorder with prior treatment failures","detailedDescription":"Eligible subjects must have either completed Study AXS-05-TRD-201 immediately prior to enrollment in this study or meet the DSM-5 criteria for major depressive disorder (MDD) without psychotic features."},"conditionsModule":{"conditions":["Treatment Resistant Depression","Major Depressive Disorder"],"keywords":["AXS-05","Treatment Resistant Depression","TRD","NMDA receptor","Refractory depression","Resistant depression","Depression","Major depression","Dextromethorphan","Bupropion","MDD"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":181,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"AXS-05 (dextromethorphan-bupropion)","type":"EXPERIMENTAL","interventionNames":["Drug: AXS-05 (dextromethorphan-bupropion)"]}],"interventions":[{"type":"DRUG","name":"AXS-05 (dextromethorphan-bupropion)","description":"\\- Titrated to AXS-05 (45 mg dextromethorphan HBr / 105 mg bupropion HCl) twice daily (up to 15 months)","armGroupLabels":["AXS-05 (dextromethorphan-bupropion)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence of Treatment-emergent AEs (TEAEs) Following Dosing With AXS-05","timeFrame":"Duration of participation was up to 15 months. TEAEs were defined as any AE with an onset date in the interval between the first study treatment dosing date and 7 days after the last study treatment dosing date."}]},"eligibilityModule":{"eligibilityCriteria":"* Completed Study AXS-05-TRD-201 OR currently meets the DSM-5 criteria for MDD without psychotic features and with prior antidepressant treatment failure\n* Agree to use adequate method of contraception for the duration of the study\n* Additional criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Clinical Research Site","city":"Little Rock","state":"Arkansas","zip":"72209","country":"United States","geoPoint":{"lat":34.74648,"lon":-92.28959}},{"facility":"Clinical Research Site","city":"Redlands","state":"California","zip":"92374","country":"United States","geoPoint":{"lat":34.05557,"lon":-117.18254}},{"facility":"Clinical Research Site","city":"Sherman Oaks","state":"California","zip":"91403","country":"United States","geoPoint":{"lat":34.15112,"lon":-118.44925}},{"facility":"Clinical Research Site","city":"Upland","state":"California","zip":"91786","country":"United States","geoPoint":{"lat":34.09751,"lon":-117.64839}},{"facility":"Clinical Research Site","city":"Miami","state":"Florida","zip":"33122","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Clinical Research Site","city":"Miami Lakes","state":"Florida","zip":"33016","country":"United States","geoPoint":{"lat":25.90871,"lon":-80.30866}},{"facility":"Clinical Research Site","city":"Orlando","state":"Florida","zip":"32081","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Clinical Research Site","city":"Chicago","state":"Illinois","zip":"60634","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Clinical Research Site","city":"Boston","state":"Massachusetts","zip":"02131","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Clinical Research Site","city":"Berlin","state":"New Jersey","zip":"08009","country":"United States","geoPoint":{"lat":39.79123,"lon":-74.92905}},{"facility":"Clinical Research Site","city":"Rochester","state":"New York","zip":"14618","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"Clinical Research Site","city":"Staten Island","state":"New York","zip":"10312","country":"United States","geoPoint":{"lat":40.56233,"lon":-74.13986}},{"facility":"Clinical Research Site","city":"Hickory","state":"North Carolina","zip":"28601","country":"United States","geoPoint":{"lat":35.73319,"lon":-81.3412}},{"facility":"Clinical Research Site","city":"Raleigh","state":"North Carolina","zip":"27609","country":"United States","geoPoint":{"lat":35.7721,"lon":-78.63861}},{"facility":"Clinical Research Site","city":"Cincinnati","state":"Ohio","zip":"45215","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Clinical Research Site","city":"Middleburg Heights","state":"Ohio","zip":"44130","country":"United States","geoPoint":{"lat":41.36144,"lon":-81.81291}},{"facility":"Clinical Research Site","city":"Media","state":"Pennsylvania","zip":"19063","country":"United States","geoPoint":{"lat":39.91678,"lon":-75.38769}},{"facility":"Clinical Research Site","city":"Dallas","state":"Texas","zip":"75243","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Clinical Research Site","city":"Friendswood","state":"Texas","zip":"77546","country":"United States","geoPoint":{"lat":29.5294,"lon":-95.20104}},{"facility":"Clinical Research Site","city":"Everett","state":"Washington","zip":"98201","country":"United States","geoPoint":{"lat":47.97898,"lon":-122.20208}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Axsome Therapeutics Website","url":"http://www.axsome.com"}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"AXS-05","description":"AXS-05 tablet, taken twice daily (up to 15 months)"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","comment":"Total number of subjects enrolled.","achievements":[{"groupId":"FG000","numSubjects":"181"}]},{"type":"COMPLETED","comment":"Number of subjects who Completed prior to study termination.","achievements":[{"groupId":"FG000","numSubjects":"11"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"170"}]}],"dropWithdraws":[{"type":"Study Terminated by Sponsor","reasons":[{"groupId":"FG000","numSubjects":"95"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"20"}]},{"type":"All Other Reasons","reasons":[{"groupId":"FG000","numSubjects":"55"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"AXS-05","description":"AXS-05 tablet, taken twice daily (up to 15 months)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"181"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"46.6","spread":"13.1"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"113"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"68"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"144"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"29"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}]},{"title":"Multiple","categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Treatment-emergent AEs (TEAEs) Following Dosing With AXS-05","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Duration of participation was up to 15 months. TEAEs were defined as any AE with an onset date in the interval between the first study treatment dosing date and 7 days after the last study treatment dosing date.","groups":[{"id":"OG000","title":"AXS-05","description":"AXS-05 tablet, taken twice daily for up to 15 months"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"}]}],"classes":[{"title":"Subjects with any TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"112"}]}]},{"title":"Subjects with suspected to be drug-related TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"65"}]}]},{"title":"Subjects with serious TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]},{"title":"Subjects with TEAEs that led to drug withdrawal","categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}]},{"title":"Subjects with TEAEs that led to withdrawal from study","categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}]},{"title":"Subjects with TEAEs that resulted in death","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Duration of participation was up to 15 months. TEAEs were defined as any AE with an onset date in the interval between the first study treatment dosing date and 7 days after the last study treatment dosing date.","eventGroups":[{"id":"EG000","title":"AXS-05","description":"AXS-05 tablet, taken twice daily for up to 15 months","deathsNumAffected":0,"deathsNumAtRisk":181,"seriousNumAffected":7,"seriousNumAtRisk":181,"otherNumAffected":38,"otherNumAtRisk":181}],"seriousEvents":[{"term":"Inappropriate antidiuretic hormone secretion","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Dictionary","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"COVID-19 pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Coronavirus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Procedural pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Gastric cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Metabolic encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Suicidal ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]},{"term":"Ovarian cyst","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181}]}],"otherEvents":[{"term":"Covid-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":15,"numAtRisk":181}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":15,"numAtRisk":181}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":12,"numAtRisk":181}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"pointOfContact":{"title":"Caroline Streicher, Senior Vice President, Clinical Research","organization":"Axsome Therapeutics, Inc","email":"cstreicher@axsome.com","phone":"212-332-5061"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2021-11-08","uploadDate":"2026-01-12T09:49","filename":"Prot_001.pdf","size":1958592},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2022-02-21","uploadDate":"2026-01-12T09:49","filename":"SAP_002.pdf","size":626310}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2025-03-25","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D061218","term":"Depressive Disorder, Treatment-Resistant"},{"id":"D003865","term":"Depressive Disorder, Major"},{"id":"D003863","term":"Depression"}],"ancestors":[{"id":"D003866","term":"Depressive Disorder"},{"id":"D019964","term":"Mood Disorders"},{"id":"D001523","term":"Mental Disorders"},{"id":"D001526","term":"Behavioral Symptoms"},{"id":"D001519","term":"Behavior"}]}},"hasResults":true}